Polarean Imaging plc announced that it has received its first de novo order for a newXENOVIEW? polariser, and provides a comprehensive update against the five growth initiatives set out at its interim results. First de novo order andsystem sales to high priority institutions: The Company has received its first de novo polariser order from a top-tier U.S. academic medical centre located in the northeast.

Polarean continues to have positive meetings and is in active negotiations with additional top-tier academic medical centres. Though there is nevercertainty as to the timing or outcome from such negotiations, nor as to the speed of utilisation, management is optimistic that these negotiations will lead to theXENOVIEW MRI technology being more widely available in medical centres throughout the United States. Driving utilisation at newly established clinical sites: Both the University of Cincinnati Children's Hospital Medical Center and the University of Missouri Health Care ("MU Health Care") continue their efforts to increase clinical utilisation of their polariser systems in patients with chronic lung disease.

Both centres have undertaken multiple clinical scans and Polarean continues to work closely with these sites to ensure increased and consistent utilisation. As with any new technology introduction, radiology departments move carefully through the initial clinical scans to ensure that the entire process comprising ordering, scheduling, acquisition, image processing/reporting and billing runs efficiently and integrates smoothly into their clinical pathways, before promoting systemwide availability. In addition, Polarean is working closely with several medical centres and their clinicians who are anticipated to be coming online in 2024 to ensure a smooth integration of XENOVIEW MRI into their infrastructure including their clinical and reimbursement operations as they embark on establishing a successful novel advanced imaging programme.

The new reimbursement APC-code (C9791) issued by the US Centers for Medicare & Medicaid Services ("CMS") in August 2023 for the XENOVIEW MRI technology corresponds to a payment range of between USD 1,201 to USD 1,300.